News >

Davids Discusses Frontline CLL Combo of Ibrutinib Plus Chemoimmunotherapy

Gina Columbus @ginacolumbusonc
Published: Friday, Mar 02, 2018

Dr. Matthew S. Davids

Matthew S. Davids, MD
Data presented at the 2017 ASH Annual Meeting by Matthew S. Davids, MD, showed that combining ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy induced negative minimum residual disease (MRD) status in bone marrow for 83% of fit, younger patients with chronic lymphocytic leukemia (CLL).

The phase II study evaluated ibrutinib combined with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. The objective response rate was 100%, including a rate of complete response (CR) with or without hematologic recovery of 40%. Thirty-seven percent of patients had CR in association with MRD negativity. Thirty-one patients initiated ibrutinib maintenance after FCR. There were no new safety signals for ibrutinib or FCR.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication